A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men
Status:
Recruiting
Trial end date:
2023-02-05
Target enrollment:
Participant gender:
Summary
This study looks at how the new medicine called NNC0480-0389 works in the body of Chinese men
when it is given at different doses together with a fixed dose of semaglutide. Participants
will get one injection of NNC0480-0389 and one injection of semaglutide - which dose of
NNC0480-0389 participants get is decided by chance.
NNC0480-0389 is a new medicine that has not been previously approved. It means that the
medicine has not yet been approved by the health authorities.
Semaglutide is a newly approved antidiabetic medicine that helps to lower blood sugar levels
in people with type 2 diabetes.
NNC0480-0389 is being developed to be given together with semaglutide. NNC0480-0389 targets a
different part of the system that regulates sugar levels in the body than semaglutide.
Therefore, it is expected that together NNC0480-0389 and semaglutide will more effectively
lower sugar levels in the blood in people with type 2 diabetes.
Participants will get 2 injections of the study medicine (one of each). It will be injected
with a needle into a skin fold on participants abdomen.
The study will last for a maximum of 72 days. Partcicipants will have 10 scheduled visits
with the study doctor. For 1 of the visits participants will stay at the clinic for 6 days (5
nights). The study includes blood sampling.